I

Incyte

Biopharmaceutical company pursuing drug discovery.

Technician Production Solution Preparation

Bioprocess & BiomanufacturingUpdated on Nov 10
Full-timeYverdon-les-Bains, SwitzerlandNo salary listedIn-person

About the Job

Requirements

  • Technical or scientific training (CFC or equivalent, Bachelor HES, DUT/BTS) in industrial pharmacy, or equivalent experience in the chemical, food, pharmaceutical, or biotechnology industry, with a minimum of 3 years of experience.
  • Availability for shift work, including weekends depending on the department.
  • Flexibility to work occasional daytime hours.
  • Ability to work in a demanding, highly regulated environment.
  • Field experience in cGMP production.

Responsibilities

  • Operate production equipment and perform in-process controls according to GMP.
  • Execute production tasks according to the defined schedule.
  • Participate in area maintenance and cleaning activities.
  • Identify quality deviations and document them in quality systems.
  • Remain available and participate in investigations.
  • Complete the training plan defined by the manager within the required timelines, both theoretical and practical.
  • Train other employees in the technician's area of competence as needed.
  • Perform activities related to batch release, including reviewing and commenting on exceptions and closing batch records.
  • Execute equipment qualification protocols for the area.
  • Contribute to continuous improvement by applying 5S principles and participating in Gemba activities in the area.
  • Set an example for other team members to ensure timely production of batches and proactively propose solutions to problems.
  • Comply with legal and regulatory requirements and company directives.

About the Company

Incyte

Biopharmaceutical company pursuing drug discovery.

Incyte develops and sells medicines by discovering and developing new drugs, focusing on diseases in inflammation, autoimmunity, and blood cancers. Its core product, Jakafi (ruxolitinib), is a JAK1/2 inhibitor approved to treat a rare blood cancer and works by blocking JAK enzymes to reduce abnormal blood cell growth. The company also expands its pipeline through research collaborations, partnerships, and acquisitions, such as the 2024 purchase of Escient Pharmaceuticals to strengthen its inflammation and autoimmune portfolio. Unlike some competitors that rely mainly on internal programs, Incyte combines in-house discovery with external collaborations and strategic deals to grow its drug candidates from early research to approved therapies. The goal is to deliver medicines that help patients with serious diseases by building a diverse, clinically validated portfolio of treatments through internal efforts and partnerships.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Wilmington, DE
Founded
1991

Recently Posted Jobs

Explore more opportunities at Incyte

See more jobs